Drugs / TRBC1/2 CAR-NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07164560 | Apr 2026 → Jan 2029 expected | peripheral T-cell lymphoma, not otherwise specified | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRBC1/2 CAR-NK cells | “Based on safety, in vivo expansion and persistence of TRBC1/2 CAR-NK cells, and preliminary efficacy results from Phase I, the recommended dose and administration schedule will...” NCT07164560 ↗ |
| Modality | Cell therapy | “Umbilical cord blood-derived NK cells transduced with lentiviral vector express anti-TRBC1 CAR” NCT07164560 ↗ |
| Route | Intravenous | “administered via intravenous infusion” NCT07164560 ↗ |
| Target | TRBC1 | “targeting TRBC1/2” NCT07164560 ↗ |